These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 39075925)

  • 1. Efficacy and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: The INITIATION study.
    Chen L; Wen B; Liu H; Wu H; Duan B; Shu H; Zhang Q; Wu X; Li M; Han Y; Kang L; Zhang M
    Diabetes Obes Metab; 2024 Oct; 26(10):4571-4582. PubMed ID: 39075925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
    Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
    Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.
    Yale JF; Aroda VR; Charbonnel B; Sinclair AJ; Trescoli C; Cahn A; Bigot G; Merino-Trigo A; Brulle-Wohlhueter C; Bolli GB; Ritzel R
    Diabetes Metab; 2020 Apr; 46(2):110-118. PubMed ID: 30366067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).
    Terauchi Y; Koyama M; Cheng X; Takahashi Y; Riddle MC; Bolli GB; Hirose T
    Diabetes Obes Metab; 2016 Apr; 18(4):366-74. PubMed ID: 26662838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.
    Liu M; Gu W; Chen L; Li Y; Kuang H; Du J; Alvarez A; Lauand F; Souhami E; Zhang J; Xu W; Du Q; Mu Y;
    Diabetes Obes Metab; 2024 Sep; 26(9):3791-3800. PubMed ID: 38922731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study.
    Malik RA; Hwu CM; Jammah AA; Arteaga-Díaz JM; Djaballah K; Pilorget V; Alvarez A; Vera C; Vikulova O
    Diabetes Obes Metab; 2024 Jul; 26(7):2811-2819. PubMed ID: 38637981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
    Wolnik B; Wiza D; Szczepanik T; Syta A; Klupa T
    J Diabetes Res; 2020; 2020():8751348. PubMed ID: 32337298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension.
    Yki-Järvinen H; Bergenstal RM; Bolli GB; Ziemen M; Wardecki M; Muehlen-Bartmer I; Maroccia M; Riddle MC
    Diabetes Obes Metab; 2015 Dec; 17(12):1142-9. PubMed ID: 26172084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1).
    Matsuhisa M; Koyama M; Cheng X; Takahashi Y; Riddle MC; Bolli GB; Hirose T;
    Diabetes Obes Metab; 2016 Apr; 18(4):375-83. PubMed ID: 26662964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study.
    Hong EG; Min KW; Lim JS; Ahn KJ; Ahn CW; Yu JM; Kim HS; Kim HJ; Kim W; Kim DH; Jang HC
    Adv Ther; 2024 May; 41(5):1967-1982. PubMed ID: 38512540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension.
    Riddle MC; Yki-Järvinen H; Bolli GB; Ziemen M; Muehlen-Bartmer I; Cissokho S; Home PD
    Diabetes Obes Metab; 2015 Sep; 17(9):835-42. PubMed ID: 25846721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.
    Bolli GB; Riddle MC; Bergenstal RM; Wardecki M; Goyeau H; Home PD;
    Diabetes Metab; 2017 Sep; 43(4):351-358. PubMed ID: 28622950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study.
    Bailey TS; Zhou FL; Gupta RA; Preblick R; Gupta VE; Berhanu P; Blonde L
    Diabetes Obes Metab; 2019 Jul; 21(7):1596-1605. PubMed ID: 30843339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
    Roussel R; d'Emden MC; Fisher M; Ampudia-Blasco FJ; Stella P; Bizet F; Cali AMG; Wysham CH
    Diabetes Obes Metab; 2018 Feb; 20(2):448-452. PubMed ID: 28736942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12-month comparison by concomitant sulphonylurea and/or glinide use.
    Terauchi Y; Riddle MC; Hirose T; Koyama M; Cheng X; Takahashi Y; Bolli GB
    Diabetes Obes Metab; 2018 Nov; 20(11):2541-2550. PubMed ID: 29888454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Take Control: A randomized trial evaluating the efficacy and safety of self- versus physician-managed titration of insulin glargine 300 U/mL in patients with uncontrolled type 2 diabetes.
    Russell-Jones D; Dauchy A; Delgado E; Dimitriadis G; Frandsen HA; Popescu L; Schultes B; Strojek K; Bonnemaire M; Roborel de Climens A; Davies M
    Diabetes Obes Metab; 2019 Jul; 21(7):1615-1624. PubMed ID: 30851006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes.
    Ritzel R; Roussel R; Giaccari A; Vora J; Brulle-Wohlhueter C; Yki-Järvinen H
    Diabetes Obes Metab; 2018 Mar; 20(3):541-548. PubMed ID: 28862801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes.
    Ritzel R; Roussel R; Bolli GB; Vinet L; Brulle-Wohlhueter C; Glezer S; Yki-Järvinen H
    Diabetes Obes Metab; 2015 Sep; 17(9):859-67. PubMed ID: 25929311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
    Sullivan SD; Bailey TS; Roussel R; Zhou FL; Bosnyak Z; Preblick R; Westerbacka J; Gupta RA; Blonde L
    Diabetes Obes Metab; 2018 Sep; 20(9):2148-2158. PubMed ID: 29938887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant-level meta-analysis of the ONWARDS 1-5 trials.
    Bajaj HS; Ásbjörnsdóttir B; Bari TJ; Begtrup K; Vilsbøll T; Rosenstock J
    Diabetes Obes Metab; 2024 Sep; 26(9):3810-3820. PubMed ID: 38951942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.